RA CAPITAL MANAGEMENT, L.P. - 24 Jun 2026 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
26 Jun 2026, 16:52:11 UTC
Prior SEC filing
24 Jun 2026
Next SEC filing
29 Jun 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.

Key filing fact

RA CAPITAL MANAGEMENT, L.P. filed Form 4 for ARS Pharmaceuticals, Inc. (SPRY) on 26 Jun 2026.

Key facts

  • This page summarizes RA CAPITAL MANAGEMENT, L.P.'s Form 4 filing for ARS Pharmaceuticals, Inc. (SPRY).
  • 1 reported transaction and 5 derivative rows are listed below.
  • Accepted by SEC: 26 Jun 2026, 16:52.

Change

  • Previous filing in this sequence was filed on 24 Jun 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (5)

CIK 0001346824 Primary reporting owner

RA CAPITAL MANAGEMENT, L.P.

Relationship
Director, 10%+ Owner
Address
200 BERKELEY STREET, 18TH FLOOR, BOSTON
Signature
/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
Signature date
26 Jun 2026
CIK 0001315082

RA Capital Healthcare Fund LP

Relationship
Director, 10%+ Owner
Address
200 BERKELEY STREET, 18TH FLOOR, BOSTON
Signature
/s/ Peter Kolchinsky, Manager of RA Capital Healthcare Fund GP, LLC, the General Partner of RA Capital Healthcare Fund, L.P.
Signature date
26 Jun 2026
CIK 0001825376

RA Capital Nexus Fund II, L.P.

Relationship
Director
Address
200 BERKELEY STREET, 18TH FLOOR, BOSTON
Signature
/s/ Peter Kolchinsky, Manager of RA Capital Nexus Fund II GP, LLC, the General Partner of RA Capital Nexus Fund II, L.P.
Signature date
26 Jun 2026
CIK 0001384859

Kolchinsky Peter

Relationship
Director, 10%+ Owner
Address
C/O RA CAPITAL MANAGEMENT, L.P., 200 BERKELEY STREET, 18TH FLOOR, BOSTON
Signature
/s/ Peter Kolchinsky, individually
Signature date
26 Jun 2026
CIK 0001619841

Shah Rajeev M.

Relationship
Director, 10%+ Owner
Address
C/O RA CAPITAL MANAGEMENT, L.P., 200 BERKELEY STREET, 18TH FLOOR, BOSTON
Signature
/s/ Rajeev Shah, individually
Signature date
26 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SPRY transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares
+30,000
Change %
Price
$0.000000*
Shares after
30,000
Date
24 Jun 2026
Ownership
See Footnotes
Underlying class
Common Stock
Underlying amount
30,000
Exercise price
$10.54
Footnotes
F1, F2, F3
SPRY transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares
+30,000
Change %
Price
$0.000000*
Shares after
30,000
Date
24 Jun 2026
Ownership
See Footnotes
Underlying class
Common Stock
Underlying amount
30,000
Exercise price
$10.54
Footnotes
F1, F2, F3
SPRY transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares
+30,000
Change %
Price
$0.000000*
Shares after
30,000
Date
24 Jun 2026
Ownership
See Footnotes
Underlying class
Common Stock
Underlying amount
30,000
Exercise price
$10.54
Footnotes
F1, F2, F3
SPRY transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares
+30,000
Change %
Price
$0.000000*
Shares after
30,000
Date
24 Jun 2026
Ownership
See Footnotes
Underlying class
Common Stock
Underlying amount
30,000
Exercise price
$10.54
Footnotes
F1, F2, F3
SPRY transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares
+30,000
Change %
Price
$0.000000*
Shares after
30,000
Date
24 Jun 2026
Ownership
See Footnotes
Underlying class
Common Stock
Underlying amount
30,000
Exercise price
$10.54
Footnotes
F1, F2, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.

Footnote F2

RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

Footnote F3

Under Dr. Kolchinsky 's arrangement with the Adviser, Dr. Kolchinsky holds the option for the benefit of the Fund and the Nexus Fund II. Dr. Kolchinsky is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.

SEC remarks

Dr. Peter Kolchinsky, a Managing Partner of the Adviser, serves on the Issuer's board of directors.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .